Compare CTM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | IMUX |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 85.8M |
| IPO Year | N/A | N/A |
| Metric | CTM | IMUX |
|---|---|---|
| Price | $1.06 | $0.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,606,863.00 | N/A |
| Revenue This Year | $23.00 | N/A |
| Revenue Next Year | $11.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.09 | N/A |
| 52 Week Low | $0.26 | $0.56 |
| 52 Week High | $2.83 | $1.39 |
| Indicator | CTM | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 36.87 |
| Support Level | $1.00 | $0.66 |
| Resistance Level | $1.17 | $0.70 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 22.92 | 25.81 |
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.